SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats

• Main Authors: Sa-nguanmoo P., Tanajak P., Kerdphoo S., Jaiwongkam T., Pratchayasakul W., Chattipakorn N., Chattipakorn S.
• 格式: 雜誌
• 出版: 2017
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85027518734&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/40077
• 機構: Chiang Mai University

© 2017 Elsevier Inc. Dipeptidyl peptidase-4 inhibitor (vildagliptin) has been shown to exert beneficial effects on insulin sensitivity and neuroprotection in obese-insulin resistance. Recent studies demonstrated the neuroprotection of the sodium-glucose co-transporter 2 inhibitor (dapagliflozin) in...